Citigroup Cuts AbbVie (NYSE:ABBV) Price Target to $230.00

AbbVie (NYSE:ABBV) had its price target trimmed by Citigroup from $235.00 to $230.00 in a research note published on Tuesday,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other equities analysts have also commented on ABBV. Bank of America increased their price target on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a report on Tuesday, November 4th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price target for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Finally, Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $249.37.

AbbVie Stock Up 0.8%

ABBV stock opened at $220.42 on Tuesday. The business’s 50-day moving average price is $224.67 and its 200-day moving average price is $218.02. The stock has a market cap of $389.56 billion, a P/E ratio of 166.98, a PEG ratio of 0.90 and a beta of 0.36. AbbVie has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter last year, the company earned $3.00 EPS. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. On average, equities research analysts expect that AbbVie will post 12.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Eagle Wealth Advisors LLC acquired a new stake in shares of AbbVie during the fourth quarter worth $263,000. FARMERS & MERCHANTS TRUST Co OF LONG BEACH lifted its position in AbbVie by 16.6% during the 4th quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 7,029 shares of the company’s stock worth $1,606,000 after acquiring an additional 1,002 shares during the period. Anchyra Partners LLC acquired a new stake in AbbVie during the 4th quarter worth about $1,155,000. First National Bank & Trust Co. of Newtown grew its stake in AbbVie by 2.1% during the 4th quarter. First National Bank & Trust Co. of Newtown now owns 11,766 shares of the company’s stock valued at $2,688,000 after purchasing an additional 239 shares during the last quarter. Finally, Aprio Wealth Management LLC increased its holdings in shares of AbbVie by 75.5% in the fourth quarter. Aprio Wealth Management LLC now owns 10,464 shares of the company’s stock valued at $2,391,000 after purchasing an additional 4,502 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Investor enthusiasm around a reported bispecific trial win and management’s renewed R&D pledge — this strengthens AbbVie’s pipeline narrative and long-term growth prospects. Does AbbVie’s Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
• Positive Sentiment: Retrospective coverage highlighting AbbVie’s strong 2025 performance reinforces confidence in management’s handling of patent cliffs and portfolio transitions. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Allergan Aesthetics unveiled new clinical and portfolio data that support continued strength in the aesthetics business — a valuable, higher-margin growth pillar for AbbVie. Allergan Aesthetics Unveils New Data Across Facial Injectables
• Positive Sentiment: On-air analyst commentary recommended staying long ABBV, adding short-term buying pressure from retail and institutional viewers. AbbVie, SLB, Amphenol, And More On CNBC’s ‘Final Trades’
• Neutral Sentiment: Coverage of AbbVie’s drug affordability deal notes management is trying to balance price/access commitments with continued R&D and patient-growth plans — reduces regulatory risk but may cap pricing upside. AbbVie Balances Drug Affordability Deal With R&D And Patient Growth Plans
• Neutral Sentiment: Investor note questioning whether recent gains leave ABBV fairly priced based on DCF and price-to-sales signals — flags valuation scrutiny even as shares rally. Is AbbVie (ABBV) Pricing Reflect Its DCF And Price To Sales Signals After Recent Gains
• Neutral Sentiment: AbbVie launched a migraine-focused awareness program (“Love in Mind”) — positive for brand, patient engagement and uptake of migraine therapies but largely a longer-term marketing play. AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine
• Negative Sentiment: Near-term earnings preview from Zacks suggests AbbVie may lack the setup for an earnings beat next week, which could increase volatility if guidance or execution disappoints. AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.